NEW YORK Natrol on Wednesday morning commented that the company is currently developing a line of four anti-aging supplements, the first of which will reach the market within the ensuing 18 months as the product and patents are finalized, Wayne Bos, Natrol president and chief executive officer, told analysts during the Roth Conference Presentation held here. “We’re at the early stage of positioning the business model and the go-to-market strategy with new, unique marketing,” Bos said.
"It’s stemming from technology that Medical Research Institute [which Natrol acquired in June] has been working on," Bos said. "We’re looking to create a unique line of premium, patented, proven anti-aging supplements."
Natrol believes the opportunity in anti-aging products for the older-than-45 demographic may be larger than that for bone/joint-health dietary supplements, which represents a $700 million category, Bos said. According to the company, approximately 110 million people are currently over the age of 45, and this age group has more disposable income than any other market segment. While approximately 15.8 million people are affected by osteoarthritis, the preventative market potential is estimated to encompass 50 million people, Bos said. "If you can imagine, if 1 percent of this over-45 age group spent $320 per annum, it would represent an approximately $350 million opportunity," Bos said.